XML 65 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Income Tax (Tables)
12 Months Ended
Dec. 31, 2023
Income Taxes [Abstract]  
Summary of Current and Deferred Tax Expense
The following table illustrates the current and deferred taxes for the periods indicated:
Years ended
December 31,
(in millions €)202320222021
Current income taxes243.13,629.64,535.0
Deferred taxes12.7(109.9)218.9
Income taxes255.83,519.74,753.9
Summary of Reconciliation of Expected Income Tax Benefit to Actual Income Tax Benefit
The following table reconciles the expected income taxes to the income tax expenses. The expected income taxes were calculated using the combined income tax rate of BioNTech SE applicable to the Group and mentioned above which was applied to profit before taxes to calculate the expected income taxes.
Years ended
December 31,
(in millions €)2023
               2022
               2021
Profit before tax1,186.112,954.115,046.4
Expected tax credit321.83,529.74,622.5
Effects
Deviation due to local tax basis6.68.99.1
Deviation due to deviating income tax rate (Germany and foreign countries)(0.1)7.39.4
Change in valuation allowance(14.3)30.63.0
Effects from tax losses and tax credits(66.5)23.219.5
Change in deferred taxes due to tax rate change(2.4)(2.3)(7.5)
Non-deductible expenses3.12.590.5
Non tax-effective income(0.6)(87.9)(0.3)
Non tax-effective share-based payment expenses7.78.715.5
Tax-effective equity transaction costs(1.2)
Adjustment prior year taxes5.5(31.5)(2.9)
Non-tax effective bargain purchase(0.7)
Other effects(5.0)30.5(3.0)
Income taxes255.83,519.74,753.9
Effective tax rate21.6 %
            27.2%
31.6%
Summary of Deferred Taxes
Deferred taxes for the periods indicated relate to the following:
Year ended December 31, 2023
(in millions €)January 1,
2023
Recognized in P&L
Recognized in OCIRecognized directly in equityDecember 31,
2023
Fixed assets15.820.2(44.4)(8.4)
Right-of-use assets(55.8)(0.8)(56.6)
Inventories 148.9(35.3)113.6
Trade and other receivables (162.7)72.7(90.0)
Lease liabilities55.22.057.2
Contract liabilities(10.0)(33.0)(43.0)
Loans and borrowings7.6(2.8)4.8
Net employee defined benefit liabilities0.7(0.1)0.6
Share-based payments 188.412.0(58.3)142.1
Other provisions11.0(1.2)9.8
Other (incl. deferred expenses)61.5(106.4)(44.9)
Tax losses / tax credits99.5(5.1)94.4
Deferred tax assets net (before valuation adjustment)360.1(77.8)(102.7)179.6
Valuation adjustment(136.7)65.1(66.4)(138.0)
Deferred tax assets / (liabilities), net (after valuation adjustment)223.4(12.7)(169.1)41.6
Thereof deferred tax assets229.620.8(169.1)81.3
Thereof deferred tax liability(6.2)(33.5)(39.7)
Year ended December 31, 2022
(in millions €)January 1,
2022
Recognized in P&L
Recognized in OCIRecognized directly in equityDecember 31,
2022
Fixed assets(6.5)22.315.8
Right-of-use assets(47.5)(8.3)(55.8)
Inventories 1.8147.1148.9
Trade and other receivables (95.6)(67.1)(162.7)
Lease liabilities48.76.555.2
Loans and borrowings23.1(15.5)7.6
Contract liabilities10.6(20.6)(10.0)
Net employee defined benefit liabilities0.9(0.5)0.30.7
Other provisions6.34.711.0
Share-based payments 8.5179.9188.4
Other (incl. deferred expenses)1.659.961.5
Tax losses / tax credits70.928.699.5
Deferred tax assets net (before valuation adjustment)14.3165.60.3179.9360.1
Valuation adjustment(81.0)(55.7)(136.7)
Deferred tax assets / (liabilities), net (after valuation adjustment)(66.7)109.90.3179.9223.4
Summary of Accumulated Tax Losses Up until the year ended December 31, 2022, our accumulated tax losses also comprised those of the German tax group. Our accumulated tax losses for the periods indicated amounted to the following:
Years ended
December 31,
(in millions €)202320222021
Corporate tax260.7352.3272.0
Trade tax 140.1204.1170.6
Years ended
December 31,
(in millions €)202320222021
Federal tax credits21.34.00.8
State tax credits8.71.60.3